Eli Lilly returns to Indianapolis after a weekend of GLP-1 dominance at ADA

Eli Lilly flew from an RC model airfield near Vista View, Florida, to Indianapolis International Airport on June 10, landing after a 2-hour, 6-minute flight in the company’s Gulfstream G500, tail N308EL. The brief trip — a roughly 600-nautical-mile hop from a recreational runway north of Fort Lauderdale — follows several days of company movements in the Southeast.

The same week, Eli Lilly executives presented at the American Diabetes Association’s 86th Scientific Sessions in Orlando, a conference that ran June 6–9. There, Lilly unveiled Phase 3 data for retatrutide, a triple-G drug that cut body weight by more than 30% in patients with obesity, a result analysts at William Blair called a “new record in the Weight Loss Olympics,” per BioSpace. The company also announced plans to submit its oral GLP-1 Foundayo (orforglipron) for type 2 diabetes approval before the end of the second quarter, using a National Priority Review Voucher, according to a June 8 company release.

Lilly’s flight pattern in the preceding days suggests the fleet was clustering around the Orlando area for the meeting. On June 7, one aircraft flew a short loop over Indianapolis — a likely repositioning — while June 4 and June 3 showed legs from Newark and Austin back to KIND. The company’s G500s are the preferred transport for CEO Dave Ricks and his executive team, who are overseeing what CNBC described this week as a “GLP-1 windfall” that Lilly is now using to fund a stepped-up M&A strategy.